Jacob P. Hulewicz

Jacob P. Hulewicz

Auto-generated profile, based on publicly available information

Jacob P. Hulewicz

Department of Chemistry and Biochemistry University of Notre Dame Notre Dame Indiana USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2020 in WIREs RNA
Verified
Journal Article
Open access
PDF file
PMPhillip McCown
Phillip McCown
ARAgnieszka Ruszkowska
Agnieszka Ruszkowska
CKCharlotte N. Kunkler
Charlotte N. Kunkler
KBKurtis Breger
Kurtis Breger
JHJacob P. Hulewicz
Jacob P. Hulewicz
JBJessica Brown
Jessica Brown
The chemical identity of RNA molecules beyond the four standard ribonucleosides has fascinated scientists since pseudouridine was characterized as the “fifth” ribonucleotide in 1951. Since then, the ever‐increasing number and complexity of modified ribonucleosides have been found in viruses and throughout all three domains of life. Such modifications can be as simple as methylations, hydroxylations, or thiolations, complex as ring closures, glycosylations, acylations, or aminoacylations, or unusual as the incorporation of selenium. While initially found in transfer and ribosomal RNAs, modifications also exist in messenger RNAs and noncoding RNAs. Modifications have profound cellular outcomes at various levels, such as altering RNA structure or being essential for cell survival or organism viability. The aberrant presence or absence of RNA modifications can lead to human disease, ranging from cancer to various metabolic and developmental illnesses such as Hoyeraal–Hreidarsson syndrome, Bowen–Conradi syndrome, or Williams–Beuren syndrome. In this review article, we summarize the characterization of all 143 currently known modified ribonucleosides by describing their taxonomic distributions, the enzymes that generate the modifications, and any implications in cellular processes, RNA structure, and disease. We also highlight areas of active research, such as specific RNAs that contain a particular type of modification as well as methodologies used to identify novel RNA modifications.This article is categorized under: RNA Processing > RNA Editing and Modification

6 September 2023 in WIREs RNA
Verified
Journal Article
Open access
KBKurtis Breger
Kurtis Breger
CKCharlotte N. Kunkler
Charlotte N. Kunkler
NONathan O'Leary
Nathan O'Leary
JHJacob P. Hulewicz
Jacob P. Hulewicz
JBJessica Brown
Jessica Brown
Despite the discovery of modified nucleic acids nearly 75 years ago, their biological functions are still being elucidated. N6‐methyladenosine (m6A) is the most abundant modification in eukaryotic messenger RNA (mRNA) and has also been detected in non‐coding RNAs, including long non‐coding RNA, ribosomal RNA, and small nuclear RNA. In general, m6A marks can alter RNA secondary structure and initiate unique RNA–protein interactions that can alter splicing, mRNA turnover, and translation, just to name a few. Although m6A marks in human RNAs have been known to exist since 1974, the structures and functions of methyltransferases responsible for writing m6A marks have been established only recently. Thus far, there are four confirmed human methyltransferases that catalyze the transfer of a methyl group from S‐adenosylmethionine (SAM) to the N6 position of adenosine, producing m6A: methyltransferase‐like protein (METTL) 3/METTL14 complex, METTL16, METTL5, and zinc‐finger CCHC‐domain‐containing protein 4. Though the methyltransferases have unique RNA targets, all human m6A RNA methyltransferases contain a Rossmann fold with a conserved SAM‐binding pocket, suggesting that they utilize a similar catalytic mechanism for methyl transfer. For each of the human m6A RNA methyltransferases, we present the biological functions and links to human disease, RNA targets, catalytic and kinetic mechanisms, and macromolecular structures. We also discuss m6A marks in human viruses and parasites, assigning m6A marks in the transcriptome to specific methyltransferases, small molecules targeting m6A methyltransferases, and the enzymes responsible for hypermodified m6A marks and their biological functions in humans. Understanding m6A methyltransferases is a critical steppingstone toward establishing the m6A epitranscriptome and more broadly the RNome.This article is categorized under: RNA Interactions with Proteins and Other Molecules > Protein‐RNA Recognition RNA Interactions with Proteins and Other Molecules > RNA‐Protein Complexes RNA Interactions with Proteins and Other Molecules > Protein‐RNA Interactions: Functional Implications

7 November 2024 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
Gowthami MahendranGowthami Mahendran
Gowthami Mahendran
KBKurtis Breger
Kurtis Breger
PMPhillip McCown
Phillip McCown
JHJacob P. Hulewicz
Jacob P. Hulewicz
TBTulsi Bhandari
Tulsi Bhandari
JBJessica Brown
Jessica Brown
Miller-Dieker syndrome (MDS) is a rare neurogenetic disorder resulting from a heterozygous deletion of 26 genes in the MDS locus on human chromosome 17. MDS patients often die in utero and only 10% of those who are born reach 10 years of age. Current treatments mostly prevent complications and control seizures. A detailed understanding of the pathogenesis of MDS through gene expression studies would be useful in developing precise medical approaches toward MDS. To better understand MDS at the molecular level, we performed RNA sequencing on RNA and mass spectrometry on total protein isolated from BJ (non-MDS) cells and GM06097 (MDS) cells, which were derived from a healthy individual and an MDS patient, respectively. Differentially expressed genes (DEGs) at the RNA and protein levels involved genes associated with phenotypic features reported in MDS patients (CACNG4, ADD2, SPTAN1, SHANK2), signaling pathways (GABBR2, CAMK2B, TRAM-1), and nervous system development (CAMK2B, BEX1, ARSA). Functional assays validated enhanced calcium signaling, downregulated protein translation, and cell migration defects in MDS. Interestingly, overexpression of methyltransferase-like protein 16 (METTL16), a protein encoded in the MDS locus, restored defects in protein translation, phosphor states of mTOR (mammalian target of rapamycin) pathway regulators, and cell migration in MDS cells. Although DNA- and RNA-modifying enzymes were among the DEGs and the intracellular SAM/SAH ratio was eightfold lower in MDS cells, global nucleoside modifications remained unchanged. Thus, this study identified specific genes and pathways responsible for the gene expression changes, which could lead to better therapeutics for MDS patients.